145 related articles for article (PubMed ID: 1685826)
1. Soluble IL2 receptor serum levels and epidermal cytokines in mycosis fungoides and related disorders.
Zachariae C; Larsen CS; Kaltoft K; Deleuran B; Larsen CG; Thestrup-Pedersen K
Acta Derm Venereol; 1991; 71(6):465-70. PubMed ID: 1685826
[TBL] [Abstract][Full Text] [Related]
2. A distinct profile of serum levels of soluble intercellular adhesion molecule-1 and intercellular adhesion molecule-3 in mycosis fungoides and Sézary syndrome.
López-Lerma I; Estrach MT
J Am Acad Dermatol; 2009 Aug; 61(2):263-70. PubMed ID: 19615537
[TBL] [Abstract][Full Text] [Related]
3. [Clinicomorphological characteristics of Sezary's disease and mycosis fungoides].
Vinogradova IuE; Giliazitdinova EA; Zamulaeva IA; Zybunova EE; Kaplanskaia IB; Kravchenko SK; Kremenetskaia AM; Lutsenko IN; Samoĭlova RS; Selivanova EN; Sidorova IuV; Shklovskiĭ-Kord NE
Ter Arkh; 2005; 77(10):61-5. PubMed ID: 16320688
[TBL] [Abstract][Full Text] [Related]
4. 13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group.
Thomsen K; Molin L; Volden G; Lange Wantzin G; Hellbe L
Acta Derm Venereol; 1984; 64(6):563-6. PubMed ID: 6084938
[TBL] [Abstract][Full Text] [Related]
5. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
6. Treatment of cutaneous T-cell lymphomas with TP-5. Evaluation of the clinical effect in 8 patients.
Przybilla B; Burg G; Schmoeckel C; Braun-Falco O
Acta Derm Venereol; 1983; 63(6):524-9. PubMed ID: 6198843
[TBL] [Abstract][Full Text] [Related]
7. [Mycosis fungoides and Sézary syndrome: diagnostic and prognostic relevance of cellular antigen expression].
Meissner K; Löning T; Rehpenning W
Hautarzt; 1991 Feb; 42(2):84-91. PubMed ID: 2037492
[TBL] [Abstract][Full Text] [Related]
8. The ultrastructure of mycosis fungoides, of Sezary's syndrome, and of Woringer-Kolopp's disease (pagetoid reticulosis).
Braune-Falco O; Schmoeckel C; Wolff HH
Bull Cancer; 1977; 64(2):191-208. PubMed ID: 143973
[TBL] [Abstract][Full Text] [Related]
9. Treatment of parapsoriasis en plaques, mycosis fungoides, and Sézary's syndrome with trioxsalen baths followed by ultraviolet light.
Fischer T; Skogh M
Acta Derm Venereol; 1979; 59(2):171-3. PubMed ID: 84498
[TBL] [Abstract][Full Text] [Related]
10. Transfer factor therapy in mycosis fungoides: a double-blind study.
Thestrup-Pedersen K; Grunnet E; Zachariae H
Acta Derm Venereol; 1982; 62(1):47-53. PubMed ID: 6175137
[TBL] [Abstract][Full Text] [Related]
11. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
12. Mycosis fungoides associated with B-cell malignancies.
Barzilai A; Trau H; David M; Feinmesser M; Bergman R; Shpiro D; Schiby G; Rosenblatt K; Or R; Hodak E
Br J Dermatol; 2006 Aug; 155(2):379-86. PubMed ID: 16882178
[TBL] [Abstract][Full Text] [Related]
13. T-cell receptor-gamma gene analysis in evolving to advancing cutaneous T-cell lymphoma.
Foo CC; Tang MB; Chong TK; Sun YJ; Tan SH
Australas J Dermatol; 2007 Aug; 48(3):156-60. PubMed ID: 17680965
[TBL] [Abstract][Full Text] [Related]
14. Photochemotherapy for mycosis fungoides: a clinical and histological study.
Lowe NJ; Cripps DJ; Dufton PA; Vickers CF
Arch Dermatol; 1979 Jan; 115(1):50-3. PubMed ID: 760657
[TBL] [Abstract][Full Text] [Related]
15. Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides.
Cen P; Duvic M; Cohen PR; Kurzrock R
J Am Acad Dermatol; 2008 Mar; 58(3):382-6. PubMed ID: 18280334
[TBL] [Abstract][Full Text] [Related]
16. Mycosis fungoides--a review of the management of 28 patients and of the recent literature.
Lenane P; Powell FC; O'Keane C; Dervan P; O'Sullivan D; Bourke E; O'Loughlin S
Int J Dermatol; 2007 Jan; 46(1):19-26. PubMed ID: 17214715
[TBL] [Abstract][Full Text] [Related]
17. Transformed mycosis fungoides: clinicopathological features and outcome.
Barberio E; Thomas L; Skowron F; Balme B; Dalle S
Br J Dermatol; 2007 Aug; 157(2):284-9. PubMed ID: 17573879
[TBL] [Abstract][Full Text] [Related]
18. The nature of mycosis fungoides.
Lawrence CM; Marks JM; Burridge A; Moss C; Ive FA; McGibbon D; Parker S; Coburn P; Shuster S
Q J Med; 1986 Mar; 58(227):281-93. PubMed ID: 3737871
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptors 2, 4 and 9 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome).
Jarrousse V; Quereux G; Marques-Briand S; Knol AC; Khammari A; Dreno B
Eur J Dermatol; 2006; 16(6):636-41. PubMed ID: 17229603
[TBL] [Abstract][Full Text] [Related]
20. O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents.
Dolan ME; McRae BL; Ferries-Rowe E; Belanich M; van Seventer GA; Guitart J; Pezen D; Kuzel TM; Yarosh DB
Clin Cancer Res; 1999 Aug; 5(8):2059-64. PubMed ID: 10473086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
